N. Ready

L. Denehy, L. Jones, W. Hornsby, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC)

Michael R. Green, E. Vokes, N. Ready, 2007 .

A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors

A. Tan, N. Ready, M. Stein, 2019, Investigational New Drugs.

Gefitinib therapy for non-small cell lung cancer

N. Ready, A. Birnbaum, 2005, Current treatment options in oncology.

Lung: Medical Oncology

N. Ready, 2005 .

Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.

N. Ready, 2005, Seminars in oncology.

Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update

L. Crinò, N. Rizvi, M. Hellmann, 2016 .

Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?

N. Ready, J. Clarke, Xiaofei Wang, 2015, Translational lung cancer research.

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Weekly Paclitaxel in Patients with Solid Tumors

R. Bukowski, N. Ready, A. Lipton, 2007, Clinical Cancer Research.

7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)

C. Rudin, R. Govindan, R. Salgia, 2015 .

NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

M. Socinski, D. Carbone, S. Peters, 2016 .

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.

E. Felip, L. Crinò, N. Rizvi, 2016 .

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial

M. Stevenson, T. Stinchcombe, N. Ready, 2022, JTO clinical and research reports.

909 Differentiation subgroups within LKB1-deficient lung cancer influence both the immune exclusion phenotype and cellular composition of the immune microenvironment

D. Carbone, Jacob M. Kaufman, K. Wood, 2021, Journal for ImmunoTherapy of Cancer.

Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer.

L. Marks, C. Kelsey, Shiva K. Das, 2015, International journal of radiation oncology, biology, physics.

CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC).

R. Govindan, P. Postmus, S. Peters, 2016 .

Local recurrence after surgery for early stage lung cancer

L. Marks, D. Hollis, T. D’amico, 2009, Cancer.

A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma

H. Safran, W. Sikov, N. Ready, 2002, Cancer.

Rovalpituzumab tesirine , a DLL 3-targeted antibody-drug conjugate , in recurrent small-cell lung cancer : a fi rst-inhuman , fi rst-in-class , open-label , phase 1 study

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness.

C. Kelsey, N. Ready, J. Clarke, 2019, Clinical lung cancer.

Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study

C. Rudin, R. Govindan, D. Carbone, 2018, Pneumologie.

A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.

A. Gajra, N. Ready, M. Perry, 2007, Lung cancer.

Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.

D. Prabhakaran, P. Armstrong, H. White, 2015, European heart journal.

Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.

P. Ascierto, P. Ott, M. Hellmann, 2017 .

Weekly Paclitaxel and Carboplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

A. Nadeem, H. Wanebo, N. Ready, 2012, American journal of clinical oncology.

Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long‐term follow‐up of a Brown University Oncology Group Phase II Study (HN‐53)

H. Wanebo, N. Ready, T. Kennedy, 2008, Head & neck.

P5-13-17: Multigene Signature Assays in Patients with Early-Stage Breast Cancer (ESBC) Receiving Neoadjuvant Chemotherapy: An NCI-Funded Systematic Review and Evidence Summary of Predictive Performance.

A. Abernethy, G. Ginsburg, G. Lyman, 2011 .

P3-14-04: Assessment of Genomic Prognostic Signatures as Predictors of Response to Neoadjuvant Chemotherapy in Patients with Early Stage Breast Cancer.

A. Abernethy, G. Ginsburg, W. Barry, 2011 .

Quality appraisal of clinical validation studies for multigene prediction assays of chemotherapy response in early-stage breast cancer.

A. Abernethy, G. Ginsburg, W. Barry, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer.

M. Berry, D. Harpole, T. D’amico, 2017, The Annals of thoracic surgery.

Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial

Michael R. Green, J. Herndon, E. Vokes, 2004 .

Challenges associated with the integration of immuno-oncology agents in clinical practice

A. Lazar, N. Ready, J. Caterino, 2022, BMC Medical Education.

Stereotactic Radiotherapy for Malignancies Involving the Trigeminal and Facial Nerves

F. Yin, S. Das, D. Brizel, 2012, Technology in cancer research & treatment.

Cetuximab, Paclitaxel, Carboplatin, and Radiation For Head and Neck Cancer: A Toxicity Analysis

T. Sio, H. Safran, H. Wanebo, 2009, American journal of clinical oncology.

Small Cell Lung Cancer

C. Rudin, R. Govindan, R. Heist, 2016, Seminars in Respiratory and Critical Care Medicine.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

A. Jimeno, M. Fenton, I. Braña, 2019, European journal of cancer.

Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results.

H. Safran, H. Wanebo, N. Ready, 1997, Seminars in oncology.

1042ODurvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study

A. Jimeno, G. Melillo, N. Ready, 2017 .

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study.

R. Govindan, Keunchil Park, S. Peters, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

C. Rudin, Dong-Wan Kim, K. Urbańska, 2022, JTO clinical and research reports.

Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer.

H. Safran, H. Wanebo, N. Ready, 1997, American journal of surgery.

Surgical Resection Is Necessary To Maximize Tumor Control in Function-Preserving, Aggressive Chemoradiation Protocols for Advanced Squamous Cancer of the Head and Neck (Stage III and IV)

H. Safran, H. Wanebo, N. Ready, 2001, Annals of Surgical Oncology.

Lymphovascular Invasion in Non–Small-Cell Lung Cancer: Implications for Staging and Adjuvant Therapy

M. Berry, T. D’amico, C. Kelsey, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Matthew D. Hellmann, Joseph D. Szustakowski, Hossein Borghaei, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer

M. Socinski, D. Carbone, S. Peters, 2017, The New England journal of medicine.

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

S. Gettinger, F. Shepherd, D. Gerber, 2017, The Lancet. Oncology.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small cell lung cancer.

Renato Martins, Nithya Ramnath, Bruce E Johnson, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

New Approaches to SCLC Therapy: From the Laboratory to the Clinic

M. Krasnow, Y. Pommier, C. Rudin, 2020 .

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

S. Gettinger, E. Felip, L. Crinò, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantifying the Dynamics of Field Cancerization in Tobacco-Related Head and Neck Cancer: A Multiscale Modeling Approach.

K. Leder, N. Ready, J. Foo, 2016, Cancer research.

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

C. Rudin, R. Govindan, D. Carbone, 2019, Clinical Cancer Research.

Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.

M. Datto, Yuan Wu, N. Ready, 2021, Clinical lung cancer.

Susceptibility loci of CNOT6 in the general mRNA degradation pathway and lung cancer risk—A re‐analysis of eight GWASs

Xifeng Wu, Hongliang Liu, Q. Wei, 2017, Molecular carcinogenesis.

Genetic variants in ABCG1 are associated with survival of nonsmall‐cell lung cancer patients

Hongliang Liu, Q. Wei, D. Christiani, 2016, International journal of cancer.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial

I. Braña, L. Siu, J. Gilbert, 2019, JAMA oncology.

New approaches to small cell lung cancer therapy : from the laboratory to the clinic.

M. Krasnow, Y. Pommier, C. Rudin, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

C. Rudin, R. Govindan, Melissa L. Johnson, 2017, The Lancet. Oncology.

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

E. Felip, L. Crinò, E. Vokes, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors

H. Hurwitz, R. Riedel, J. Bendell, 2012, Cancer Chemotherapy and Pharmacology.

Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.

P. Szlosarek, L. Krug, J. Bomalaski, 2020, Clinical lung cancer.

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

M. Hellmann, V. Moreno, J. Eder, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

W. Barry, J. Herndon, M. Kelley, 2017, Cancer investigation.

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

E. Vokes, G. Otterson, H. Pang, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small Cell Lung Cancer

C. Rudin, R. Govindan, B. Loo, 2022 .

Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.

E. Vokes, Mark R. Green, H. Pang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small Cell Lung CancerPractice Guidelines in Oncology

C. Rudin, R. Govindan, B. Loo, 2011 .

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy.

E. Felip, L. Crinò, N. Rizvi, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial

P. Jänne, E. Vokes, Mark R. Green, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Image-Guided Percutaneous Thermal Ablation for the Palliative Treatment of Chest Wall Masses

T. Dipetrillo, D. Dupuy, W. Mayo-Smith, 2007, American journal of clinical oncology.

Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer.

M. Berry, T. D’amico, C. Kelsey, 2011, The Journal of thoracic and cardiovascular surgery.

Selective Organ Preservation in Operable Locally Advanced Head and Neck Squamous Cell Carcinomas Guided by Primary Site Restaging Biopsy: Long-Term Results of Two Sequential Brown University Oncology Group Chemoradiotherapy Studies

H. Wanebo, N. Ready, R. Rathore, 2011, Annals of Surgical Oncology.

Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.

R. Clough, L. Marks, T. D’amico, 2009, International journal of radiation oncology, biology, physics.

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

R. Govindan, Keunchil Park, S. Peters, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of induction chemotherapy in sinonasal malignancies: a systematic review

R. Carrau, N. Ready, I. Barak, 2018, International forum of allergy & rhinology.

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations

T. Burns, T. Stinchcombe, G. Otterson, 2023, ESMO open.

Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

M. Berry, D. Harpole, S. McCall, 2017, Clinical Cancer Research.

Local failure in resected N1 lung cancer: implications for adjuvant therapy.

M. Berry, D. Yoo, C. Kelsey, 2012, International journal of radiation oncology, biology, physics.

How Well Does the New Lung Cancer Staging System Predict for Local/Regional Recurrence After Surgery?: A Comparison of the TNM 6 and 7 Systems

L. Marks, T. D’amico, D. Yoo, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer.

Melissa L. Johnson, G. Curigliano, D. Morgensztern, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

G. Giaccone, F. Hodi, S. Gettinger, 2018, European journal of cancer.

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.

P. Ascierto, P. Ott, M. Hellmann, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.

H. Cohen, M. Socinski, R. Govindan, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.

J. Crawford, D. Yoo, C. Kelsey, 2016, Lung cancer.

Adaptive planning using positron emission tomography for locally advanced lung cancer: A feasibility study.

C. Kelsey, J. Adamson, N. Ready, 2016, Practical radiation oncology.

Treatment‐induced changes in vocal cord mobility and subsequent local recurrence after organ preservation therapy for laryngeal carcinoma

G. Broadwater, D. Yoo, N. Ready, 2012, Head & neck.

Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV).

H. Safran, H. Wanebo, N. Ready, 1999, Seminars in radiation oncology.

Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer.

T. Dipetrillo, D. Dupuy, W. Mayo-Smith, 2006, Journal of vascular and interventional radiology : JVIR.

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

L. Urban, E. Felip, Han Chang, 2023, Journal for ImmunoTherapy of Cancer.

Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.

H. Safran, H. Wanebo, N. Ready, 1999, Seminars in radiation oncology.

Smoking history predicts for increased risk of second primary lung cancer: A comprehensive analysis

T. D’amico, C. Kelsey, N. Ready, 2015, Cancer.

Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer

J. Holmlund, N. Ready, L. Leopold, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive‐Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE)

E. Vokes, J. Crawford, H. Pang, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817

L. Urban, E. Felip, L. Paz-Ares, 2019 .

Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.

R. Coleman, M. Berry, L. Marks, 2015, Practical radiation oncology.

Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

Matthew D. Hellmann, Joseph D. Szustakowski, Hossein Borghaei, 2018, Clinical Trials.

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

M. Buyse, S. Gettinger, T. Lynch, 2013 .

Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.

T. Stinchcombe, T. Leblanc, N. Ready, 2022, Lung cancer.

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial.

M. Edelman, P. Janne, J. Herndon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?

R. Coleman, T. D’amico, C. Kelsey, 2013, The Journal of thoracic and cardiovascular surgery.

Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer

John P Kirkpatrick, Oana Craciunescu, James R MacFall, 2012, Clinical Cancer Research.

Pathologic Response After Neoadjuvant Carboplatin and Weekly Paclitaxel for Early-Stage Lung Cancer: A Brown University Oncology Group Phase II Study

T. Dipetrillo, N. Ready, H. Safran, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

ORAL02.01: Safety and Efficacy of Single‐Agent Rovalpituzumab Tesirine, a DLL3‐Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology

C. Rudin, R. Govindan, L. Byers, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1528PDInitial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)

S. Clarke, K. Urbańska, B. Markman, 2017 .

A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy

C. Rudin, L. Krug, P. Fracasso, 2016 .

MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial

D. Jäger, P. Ascierto, P. Sharma, 2017 .

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).

E. Vokes, N. Rizvi, P. Baas, 2015 .

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

S. Gettinger, F. Shepherd, D. Gerber, 2015 .